News

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9…

9 months ago

Noom To Streamline Access to Zepbound® Vials with Noom GLP-1 Companion Through Integration with LillyDirect® Pharmacy Provider

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and…

9 months ago

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…

9 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

9 months ago

SS Innovations Achieves Significant Milestones in 2024

The Company’s award winning SSi Mantra surgical robotic system has completed over 3,500 surgeries and is clinically validated to perform…

9 months ago

Safety Shot Provides Business Update from CEO Jarrett Boon

SCOTTSDALE, Ariz., March 31, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness…

9 months ago

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune…

9 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers…

9 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

9 months ago

LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society

Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical…

9 months ago